SIBIA Neurosciences


Aug 11, 99

12:30 ET SIBIA Neurosciences, Inc. Reports Financial Results For Second Quarter 1999

 
Aug 02, 99

09:04 ET Merck Acquires SIBIA Neurosciences, Inc., a California-Based Biotechnology Firm; Acquisition Augments Merck's Drug Discovery Program

 
Jul 21, 99

08:30 ET SIBIA Neurosciences Announces Results From Two Phase 2 Studies Of SIB-1508Y for Parkinson's Disease

 
Jul 15, 99

08:31 ET SIBIA Neurosciences Licenses Patented Transcription Based Assay Technology to Pharmacia & Upjohn

 
Jun 24, 99

08:30 ET SIBIA Neurosciences, Inc. Announces License of Patented Transcription-Based Assay Technology to American Home Products Corporation

 
May 28, 99

08:30 ET SIBIA Neurosciences, Inc. Announces Filing of Counterclaim Against Pfizer Inc. for Patent Infringement

 
May 26, 99

08:35 ET SIBIA Neurosciences and Lilly Announce Nicotinic Receptor Drug Discovery and Development Collaboration Focusing on Central Nervous System Disorders

 
May 13, 99

08:01 ET SIBIA Neurosciences, Inc. Announces Suit Filed by Pfizer, Inc.

 
May 07, 99

08:00 ET SIBIA Neurosciences, Inc. Reports Financial Results for the First Quarter Ended March 31, 1999

 
May 05, 99

08:03 ET SIBIA Neurosciences, Inc. Names Carla M. Suto, Ph.D. Vice President, HTS and Technology Development

 
Apr 14, 99

08:02 ET SIBIA Neurosciences, Inc. Announces License of Patented Transcription Based Assay Technology to SmithKline Beecham

 
Mar 30, 99

08:02 ET SIBIA Neurosciences, Inc. Announces License of Patented Transcription Based Assay Technology to Bristol-Myers Squibb

 
Mar 29, 99

08:01 ET SIBIA Neurosciences, Inc. Reports Novel Findings on Selective Compounds

 
Mar 26, 99

08:00 ET SIBIA Neurosciences, Inc. Reports Financial Results for Year-End and Fourth Quarter Ended December 31, 1998

 
Mar 15, 99

08:06 ET SIBIA Neurosciences Announces Issuance of United States Patents

 
Feb 01, 99

15:15 ET SIBIA Neurosciences Obtains a Permanent Injunction Against Cadus

 
Jan 19, 99

13:15 ET SIBIA Neurosciences Announces Granting of Key Foreign Patents for Technology Involved in its Recent Successful Litigation Against Cadus Pharmaceuticals, Inc.

 
Jan 07, 99

08:03 ET SIBIA Neurosciences Completes Phase 1 Multiple Dose Study of SIB-1553A and Initiates Phase 2 Study in Alzheimer's Disease Patients

 
Jan 04, 99

08:00 ET SIBIA Neurosciences Initiates Second Phase 2 Study Of SIB-1508Y for Parkinson's Disease

 
Dec 21, 98

08:02 ET SIBIA Neurosciences Awarded $18 Million Verdict in Patent Infringement Lawsuit Against Cadus Pharmaceutical Corp.

 
Nov 16, 98

11:45 ET SIBIA Neurosciences, Inc. Reports on Progress in All Drug Discovery Programs at the Society for Neuroscience Meeting

 
Nov 11, 98

19:13 ET SIBIA Neurosciences, Inc. Names Stephen F. Keane Vice President, Corporate Development

 
Nov 10, 98

19:16 ET SIBIA Neurosciences, Inc. Reports Financial Results for Third Quarter Ended September 30, 1998

 
Nov 04, 98

19:47 ET SIBIA Neurosciences Reports Neuroprotective Potential of Neuronal Nicotinic Acetylcholine Receptor Ligands

 
Oct 12, 98

19:47 ET SIBIA Neurosciences Announces Issuance of United States Patents

 
Aug 24, 98

06:14 ET SIBIA Neurosciences, Inc. Announces Favorable Court Orders Regarding Its Transcription Based Assay Patent

 
Jul 31, 98

06:17 ET SIBIA Neurosciences, Inc. Reports Financial Results For Second Quarter 1998

 


Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2005 PR Newswire Association LLC. ALL Rights Reserved.
A United Business Media company.